Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Targeting the PI3K/mTOR pathway

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.12
Views: 3411

Dr Lewis Cantley – Dana-Farber Cancer Institute, Boston, USA

Dr Lewis Cantley talks to ecancer about PI3K and the development of inhibitors for clinical use at IMPAKT 2012 in Brussels, May 2012.


PI3K, phosphoinosititde 3-kinase is a signalling pathway that controls growth. PI3K is the most frequently mutated gene in breast cancer. Currently, there are 20 inhibitors in phase 1 or 2 trials.


Dr Cantley mentions that there has been good response in phase 1 trials, but while many patients had very good reactions, others did not respond.


The message to take away from this is that doctors should be more aggressive in doing mutational analyses and, more importantly, that this information become more accessible for retroactive analysis for other targetable mutations. 


Filming Supported by Amgen

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation